Body mass index (BMI) of 35 kg/m2 or more. 
Significant metabolic and endocrine diseases. 
Diagnosis of cancer. 
Use of steroids or drugs that interfere with the metabolism of estrogen. 
Use of any systemic estrogen, progestin, or DHEA in the eight weeks prior to randomization. 
Use of alternative therapies or natural products to treat postmenopausal symptoms in the four weeks prior to randomization. 
Palpable fibroids or uterine prolapse: Grade 2 or 3. 
Cigarette smoking       
    

NCT00317148_exc_T1
Measurement
Body mass index (BMI)
NCT00317148_exc_T2
Value
35 kg/m2 or more
NCT00317148_exc_T3
Condition
metabolic diseases
NCT00317148_exc_T4
Condition
endocrine diseases
NCT00317148_exc_T5
Condition
cancer
NCT00317148_exc_T6
Drug
steroids
NCT00317148_exc_T7
Drug
drugs that interfere with the metabolism of estrogen
NCT00317148_exc_T8
Drug
systemic estrogen
NCT00317148_exc_T9
Drug
systemic progestin
NCT00317148_exc_T10
Drug
DHEA
NCT00317148_exc_T11
Temporal
in the eight weeks prior to randomization
NCT00317148_exc_T12
Scope
systemic estrogen, progestin, or DHEA
NCT00317148_exc_T13
Procedure
alternative therapies
NCT00317148_exc_T14
Drug
natural products
NCT00317148_exc_T15
Condition
postmenopausal symptoms
NCT00317148_exc_T16
Temporal
in the four weeks prior to randomization
NCT00317148_exc_T17
Scope
alternative therapies or natural products
NCT00317148_exc_T18
Condition
Palpable fibroids
NCT00317148_exc_T19
Condition
uterine prolapse
NCT00317148_exc_T20
Measurement
Grade
NCT00317148_exc_T21
Value
2 or 3
NCT00317148_exc_T22
Scope
Palpable fibroids or uterine prolapse
NCT00317148_exc_T23
Condition
Cigarette smoking